李佳蕊

Publications

2026

Dual-system engineered bacteria and dendritic cells enable precise intratumoral IL-12 delivery and potent antitumor immunity.

Deng Y#, Liang H#, Wan AH#, Liu C#, Yan S#, Li J, Xiao M, Zhou Q, Liu R, Zhang Z, Zhang H, Cheng H, Fu C, Yao Q, Fang J, Neumann S, Wang Q, Huang J*, Wang Z*, Wan G*.

Cell Rep Med. 2026 Jun 16;7(6):102801.·2026·DOI

2024

A multidimensional platform of patient-derived tumors identifies drug susceptibilities for clinical lenvatinib resistance.

Sun L, Wan AH, Yan S, Liu R, Li J, Zhou Z, Wu R, Chen D, Bu X, Ou J, Li K, Lu X, Wan G*, Ke Z*.

Acta Pharm Sin B. 2024 Jan;14(1):223-240.·2024·DOI

2023

Biological informed graph neural network for tumor mutation burden prediction and immunotherapy-related pathway analysis in gastric cancer.

Liu C#, Wan AH#, Liang H#, Sun L, Li J, Yang R, Li Q, Wu R, Hu K, Yang Y, Cai S*, Wan G*, He W*.

Comput Struct Biotechnol J. 2023 Sep 22;21:4540-4551.·2023·DOI

2022

Application and prospect of circulating tumor cell in colorectal cancer immunotherapy

Wan AH, Li J, Xin W*, Wan G*.

Acta Pharm Sin. 2022, 57(9): 2590-2600·2022·DOI

RNA and RNA Derivatives: Light and Dark Sides in Cancer Immunotherapy.

Deng Y#, Xiao M#, Wan AH#, Li J, Sun L, Liang H, Wang QP, Yin S, Bu X, Wan G*.

Antioxid Redox Signal. 2022 Dec;37(16-18):1266-1290.·2022·DOI